Lineage Cell Therapeutics (LCTX) vs Protalix BioTherapeutics (DE) (PLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Protalix BioTherapeutics (DE) (PLX) has outperformed Lineage Cell Therapeutics (LCTX) over the past year, gaining 8.4% versus a loss of 45.2%. Over five years, PLX leads with a +120.3% price change compared with -59.7% for LCTX. Lineage Cell Therapeutics is the larger company by market cap ($261.8 million vs $217.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LCTX | PLX |
|---|---|---|
| Share price | $1.04 | $2.70 |
| Market cap | $261.76M | $217.54M |
| 1-day change | +9.22% | -0.37% |
| YTD return | -43.26% | +50.56% |
| 1-year return | -45.23% | +8.40% |
| 5-year return | -59.68% | +120.33% |
| P/E ratio (TTM) | — | 11.74 |
| Forward P/E | — | 4.35 |
| EPS (TTM) | $-0.19 | $0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.09 | $3.19 |
| 52-week low | $0.88 | $1.60 |
| Distance from 52-week high | -50.48% | -15.36% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +431.40% | +307.41% |
| Average volume | 1.15M | 732.64K |
| Shares outstanding | 252.91M | 80.57M |
| Employees | 72 | 226 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLX has outperformed LCTX by 53.6 percentage points over the past year.
About Lineage Cell Therapeutics
LCTX stock →Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 72 employees
About Protalix BioTherapeutics (DE)
PLX stock →Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees
LCTX vs PLX FAQ
Which is bigger, Lineage Cell Therapeutics or Protalix BioTherapeutics (DE)?
Lineage Cell Therapeutics (LCTX) is larger, with a market capitalization of $261.76M compared with $217.54M for Protalix BioTherapeutics (DE) (PLX).
Which stock has performed better over the past year, LCTX or PLX?
PLX returned +8.40% over the past 12 months, compared with -45.23% for LCTX (price return, excluding dividends). Past performance does not predict future results.
Are Lineage Cell Therapeutics and Protalix BioTherapeutics (DE) in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.